First-Line Nivolumab/Ipilimumab Improves Survival in Unresectable Hepatocellular Carcinoma

First Look With ASCO Daily News presents Dr. Peter Galle from the University Medical Center Mainz on the results of CheckMate-9DW comparing first-line nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma.

Read the full abstract (LBA4008) from the 2024 ASCO Annual Meeting: https://meetings.asco.org/abstracts-p...

For more on ASCO24, visit https://dailynews.ascopubs.org/meetin...

• #education
• #cancer
• #cancer_care
• #health_care
• #oncology
• #american_society_of_clinical_oncology
• #asco
• #asco24